Insight Molecular Diagnostics (IMDX) Net Margin (2020 - 2026)
Insight Molecular Diagnostics (IMDX) posted Net Margin of 35131.25% for Q1 2026, down 1643.17% sequentially from 2015.36% in Q4 2025, and down 3481923.0% YoY from N/an in Q1 2025.
Insight Molecular Diagnostics (IMDX) Net Margin (2020 - 2026) Analysis & Trends
Insight Molecular Diagnostics has reported Net Margin for 7 years, with the latest figure at 35131.25% in Q1 2026.
- Quarterly Net Margin fell 3481923.0% year-over-year to 35131.25% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2811.34% (down 129528.0% YoY) and the FY2025 annual result came in at 1238.52%, up 200050.0% from the prior year.
- Net Margin declined to 35131.25% in Q1 2026 per IMDX's latest filing, from 2015.36% in the prior quarter.
- Over five years, Net Margin peaked at 227.78% in Q4 2022 and troughed at 35131.25% in Q1 2026.
- A 5-year average of 5501.51% and a median of 2255.11% in 2024 frame the typical range for Net Margin.
- The sharpest annual moves came in 2023 and 2026: Net Margin jumped 1280992 bps in 2023, then tumbled 3481923 bps in 2026.
- Over 5 years, Net Margin stood at 227.78% in 2022, then plunged by 1955 bps to 4225.8% in 2023, then soared by 47 bps to 2255.11% in 2024, then grew by 11 bps to 2015.36% in 2025, then tumbled by 1643 bps to 35131.25% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 35131.25%, 2015.36%, and 4174.62% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 14.65% |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 13.89% |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 27.82% |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 18.47% |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 5.52% |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | -12.22% |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 17.86% |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 22.67% |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 10.65% |
| 10 | Insight Molecular Diagnostics | 172.42 Mn | 143.49 Mn | 15,000.00 | -35,131.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35,131.25% |
| Dec 31, 2025 | -2,015.36% |
| Sep 30, 2025 | -4,174.62% |
| Jun 30, 2025 | -1,880.69% |
| Mar 31, 2025 | -312.02% |
| Dec 31, 2024 | -2,255.11% |
| Sep 30, 2024 | -11,733.04% |
| Jun 30, 2024 | -4,410.58% |
| Mar 31, 2024 | -5,303.98% |
| Dec 31, 2023 | -4,225.80% |
| Sep 30, 2023 | -1,558.74% |
| Jun 30, 2023 | -1,866.95% |
| Mar 31, 2023 | 1.65% |
| Dec 31, 2022 | 227.78% |
| Sep 30, 2022 | -14,368.66% |
| Jun 30, 2022 | -3,532.49% |
| Mar 31, 2022 | -985.73% |
| Dec 31, 2021 | -999.86% |
| Sep 30, 2021 | -1,402.44% |
| Jun 30, 2021 | -516.90% |